UPDATE: ISI Group Raises PT to $27 on Hologic Following Guidance Raise
ISI Group maintained Hologic (NASDAQ: HOLX) with a Strong Buy rating and raised the price target from $25.50 to $27.00.
ISI Group commented, "Going forward, we expect increased adoption of 3D Tomo (as presaged by the continued sequential backlog increase) and Panther (Diagnostics) to drive growth upside. In the NT, receipt of a potential CMS reimbursement code for 3D Tomo will be a significant catalyst. Given our thesis for a new product cycle accelerating growth, we are reiterating our Strong Buy rating of HOLX shares and raising our price target from $25.50 to $27.00."
Hologic closed at $23.25 on Monday.
Latest Ratings for HOLX
|Feb 2017||Bank of America||Downgrades||Buy||Neutral|
|Jan 2017||Deutsche Bank||Initiates Coverage On||Buy|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.